Genetically Modified Rodent Parasites Reveal Clues for Vivax Malaria Vaccine

Finding new ways to block malaria before it infects human liver cells remains a major global health hurdle, especially because the parasite Plasmodium vivax creates dormant liver stages that trigger relapses months or years later. Researchers have long struggled to test human vaccine candidates because obtaining enough laboratory-produced sporozoites, the infectious stage injected by mosquitoes, is extremely difficult without human or primate hosts.

To bypass this bottleneck, a research team engineered surrogate rodent malaria parasites carrying two key human vaccine targets. The study, published in PLOS Neglected Tropical Diseases, details how scientists used a genetic replacement strategy to swap native parasite genes in Plasmodium berghei with their human-infecting P. vivax counterparts, creating stable chimeric lines for laboratory evaluation.

How Rodent Parasites Became Stand-Ins for Human Malaria Targets

The research team focused on two specific pre-erythrocytic proteins known as SSP3, standing for sporozoite surface protein 3, and SPECT1, standing for sporozoite microneme protein essential for cell traversal. Both proteins play vital roles when the parasite moves through skin tissue, crosses liver barriers, and invades host cells. Using a two-step gene insertion and marker-removal technique, the authors successfully replaced the mouse parasite genes with the full-length coding sequences for P. vivax SSP3 and SPECT1.

A series of biological fitness tests confirmed that these genetic modifications did not harm the parasite. The transgenic organisms developed normally in both mice and mosquitoes, producing oocysts and salivary gland sporozoites in numbers comparable to wild-type strains. When researchers introduced these modified sporozoites into human hepatoma cell monolayers, the parasites demonstrated typical growth and liver-stage development.

Antibody Inhibition and In Vivo Challenge Results

After confirming that the transgenic parasites matured normally, the investigators tested whether antibodies raised against recombinant versions of SSP3 and SPECT1 could block infection. In laboratory assays, antisera directed against PvSSP3 reduced hepatocyte invasion by a mean of 27 percent, while antisera against PvSPECT1 achieved a mean inhibition of 14 percent.

However, the transition from laboratory inhibition to living animal protection yielded mixed outcomes. When vaccinated mice were challenged with the transgenic parasites via intravenous injection, animals immunized with the PvSSP3 candidate showed no statistically significant protection compared to control groups. In contrast, mice immunized with the PvSPECT1 candidate achieved sterile protection in 10 percent of the test subjects, meaning those animals remained entirely free of blood-stage parasitemia.

Why Laboratory Inhibition Might Not Equal Full Protection

The study authors note that achieving only modest in vivo protection despite successful antibody generation highlights a common hurdle in malaria vaccine development. Partial inhibition in glass dishes does not automatically translate into sterilizing immunity inside a living host organism. Furthermore, the recombinant construct used for SSP3 covered only a partial fragment of the protein, which may have lacked critical structural folding needed to elicit strong neutralizing antibodies.

Another crucial factor involves the method of infection. Injecting sporozoites directly into the bloodstream via intravenous routes bypasses the natural skin stage, a vital phase where antibodies normally act to restrict parasite motility and block vascular access. The authors suggest that future evaluations should test these vaccine candidates using natural mosquito bites or intradermal delivery routes, alongside more potent clinical adjuvants, to determine their true potential for eliminating P. vivax malaria.

The research was published in PLOS Neglected Tropical Diseases on October 22, 2026.